Activation of AMP-activated protein kinase decreases receptor activator of NF-κB ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells
详细信息 查看全文
- 作者：Maki Yokomoto-Umakoshi pinyan@med.shimane-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Ippei Kanazawa ; ippei.k@med.shimane-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Ayumu Takeno atakeno@med.shimane-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Ken-ichiro Tanaka ken1nai@med.shimane-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Masakazu Notsu mnotsu25@med.shimane-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Toshitsugu Sugimoto sugimoto@med.shimane-u.ac.jp" class="auth_mail" title="E-mail the corresponding author
- 关键词：AMP-activated protein kinase ; Osteocyte ; RANKL ; Sclerostin ; Mevalonate pathway
- 刊名：Biochemical and Biophysical Research Communications
- 出版年：2016
- 出版时间：22 January 2016
- 年：2016
- 卷：469
- 期：4
- 页码：791-796
- 全文大小：939 K
文摘
- •
There are no studies on effects of AMPK activation on RANKL and sclerostin expressions in osteocytes.
- •
There are no studies on the roles of mevalonate pathway in osteocytes.
- •
AMPK activation decreased RANKL and increased sclerostin expression in MLO-Y4 cells by inhibiting mevalonate pathway.
- •
Simvastatin decreased RANKL expression and increased sclerostin expression in MLO-Y4 cells.